openPR Logo

Press Releases from mivenion GmbH (6 total)

mivenion receives market authorization for Xiralite® in Canada

Fluorescence optical imaging (FOI) with the Xiralite® fluorescence imaging system X4 is a sensitive and safe medical procedure for visualization of altered microcirculation in the hands in early and late stages of different diseases such as rheumatoid arthritis, psoriatic arthritis, scleroderma, osteoarthritis or Raynaud’s syndrom. Xiralite® is CE marked and already established in five European countries. The whole procedure is highly standardized, very sensitive, fast, and convenient for the patients.

mivenion announces 4 abstracts for fluorescence optical imaging using the Xirali …

Highlights include: • ICG-enhanced fluorescence optical imaging (FOI) is able to detect typical inflammatory changes in subjects with arthralgia and psoriasis prior to signs of clinically established arthritis. The detection of typical inflammatory changes in subjects with cutaneous manifestations of psoriasis or family history of psoriasis and joint pain but without clinical signs of synovitis or tendinitis suggests that a non-arthritic, subclinical disease stage may precede the onset of clinically active

mivenion to establish Rheumascan at Karolinska Institutet, Stockholm, Sweden

About 5% of the patients attending primary care physicians intermittently suffer from swelling and tenderness of the hand joints. In many cases, inflammatory joint diseases such as rheumatoid arthritis or psoriatic arthritis are the main cause of the disease symptoms and, without treatment, may lead to poor outcome and lifelong suffering. In recent years there is increasing evidence that early diagnosis and treatment of arthritis may effectively stop the progression

mivenion receives ISO 13485 certification for Xiralite® manufacturing and distr …

mivenion has received the official ISO 13485:2003 + AC:2009 certification as a medical device manufacturer. Published in 2003, the ISO 13485 standard outlines the requirements for a comprehensive quality management system for all aspects of the design and manufacturing process for medical devices. The certification covers the design, development, manufacturing, and distribution of the patented Xiralite® fluorescence camera system and its XiraView® software. “We are delighted that we can announce

mivenion GmbH and PTB Berlin report patent grants for imaging of inflammation

mivenion GmbH announces that it has secured patent protection for its key technology of optical imaging of inflammation. The patent rights covering diagnostic technologies for the optical rheumatoid arthritis imaging were exclusively licensed from the Physikalisch-Technische Bundesanstalt (PTB Berlin). Now, mivenion and PTB Berlin have been granted its patent by the U.S. Patent and Trademark Office in February 2011, followed by a grant by the European Patent Office in December

mivenion targets musculoskeletal imaging experts at ECR 2011

mivenion GmbH, the leading company in optical imaging of arthritis, will exhibit its groundbreaking Rheumascan workstation Xiralite® X4 and the most advanced XiraView 3.6 software for diagnostic imaging of inflammation in the hands at the forthcoming annual European Congress of Radiology (ECR) in Vienna, Austria, March 4-7. The ECR is one of the largest medical meetings worldwide and the second largest radiological congress, with around 19,000 participants from

Go To Page:   1 2 3 4 5 6 7 8 9 10